Engineered immune cells take on tough lupus cases
NCT ID NCT07403097
First seen Feb 17, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This early-stage study is testing a new treatment called PTOC1 cells, which are a type of CAR-T cell therapy, for people with severe systemic lupus erythematosus (SLE) that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target and attack lupus-causing cells. The study will enroll 18 participants to check if the treatment is safe and can reduce disease activity, with the goal of controlling the condition long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Chongqing Medical University
RECRUITINGChongqing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.